Sunovion Pharmaceuticals Inc., of Marlborough, Mass., published results from two pivotal trials supporting FDA approval of Latuda (lurasidone HCL) for major depressive episodes associated with bipolar I disorder in The American Journal of Psychiatry. The two double-blind, randomized, placebo-controlled, six-week trials showed that Latuda significantly reduced symptoms of depression as monotherapy and as adjunctive therapy, compared to placebo, as measured by the Montgomery-Asberg Depression Rating Scale.